Mirza Hamirani, MD
Nephrology · Vienna, WVNPI 1861460099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$840
- OPKO Pharmaceuticals, LLC$780
- Akebia Therapeutics Inc$712
- Vifor Pharma, Inc.$692
- Amgen$692
- Otsuka America Pharmaceutical, Inc.$640
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,85991%
- Education$6959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 47 | $840 |
| OPKO Pharmaceuticals, LLC | 52 | $780 |
| Akebia Therapeutics Inc | 39 | $712 |
| Vifor Pharma, Inc. | 49 | $692 |
| Amgen | 29 | $692 |
| Otsuka America Pharmaceutical, Inc. | 36 | $640 |
| Bayer | 33 | $621 |
| Ardelyx, Inc. | 24 | $469 |
| Travere Therapeutics, Inc. | 22 | $298 |
| Mallinckrodt Hospital Products Inc. | 15 | $261 |
| Calliditas Therapeutics US Inc. | 10 | $234 |
| Alkermes, Inc. | 12 | $205 |
| Novartis | 7 | $152 |
| Novo Nordisk | 8 | $141 |
| Lilly USA, LLC | 8 | $130 |
| Aurinia Pharma U.S., Inc. | 6 | $118 |
| Mallinckrodt Enterprises LLC | 3 | $68 |
| GSK | 4 | $64 |
| Johnson & Johnson | 3 | $62 |
| Baxter Healthcare | 3 | $54 |
| Corcept Therapeutics | 3 | $45 |
| Mylan Specialty L.p. | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi | 1 | $19 |
| Angiodynamics, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| AbbVie | 1 | $14 |
How this compares
$7,554 in reported general payments places this provider in the 90th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 29 | $154,174 |
| RenvelaSevelamer Carbonate | 11 | $50,931 |
| VeltassaPatiromer Calcium Sorbitex | 29 | $50,039 |
| Sevelamer Carbonate | 124 | $29,397 |
| ProsolParenteral Amino Acid 20% No.1 | 116 | $18,524 |
| FarxigaDapagliflozin Propanediol | 17 | $17,814 |
| Cinacalcet Hcl | 35 | $8,473 |
| Calcitriol | 375 | $5,981 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 17 | $4,800 |
| Calcium Acetate | 74 | $4,262 |
| Allopurinol | 335 | $2,825 |
| Midodrine Hcl | 38 | $2,332 |
| Bumetanide | 67 | $2,187 |
| Hydralazine Hcl | 117 | $1,144 |
| Amlodipine Besylate | 125 | $689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $840 | $17,81417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 55 nephrology providers in West Virginia.
Other nephrology in Vienna
- Julian EspirituSouth Charleston$215K
- Abdul ZanabliS Charleston$31K
- Murad KheetanHuntington$25K
- Arijit ChakravartyMorgantown$19K
- Asif RahmanCharleston$8K
- Michael CollinsHuntington$7K
- Khan ShabihCharleston$6K
- Faroug SulimanCharleston$6K
- Ahmad EterBeckley$5K
- Rebecca SchmidtMorgantown$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.